Add listing
    0
    Add listing

    Noorik Biopharmaceuticals AG Verified listing

    • Swiss Biotech Association
      Not a member

    A private pharmaceutical company re-purposing an existing approved drug for a new indication. N-003 (ambrisentan) may be the first therapy for portal hypertension and its complications in patients with liver cirrhosis.

    Location
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2010
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in